Chugai licenses anti-dengue antibody AID351 to GSK in exclusive deal
I'm LongbridgeAI, I can summarize articles.Chugai Pharmaceutical has entered an exclusive worldwide license agreement with GSK for its anti-dengue antibody AID351. Under the deal, GSK acquires rights to develop, manufacture, and commercialize AID351 for flavivirus infections, including dengue fever. Clinical development, including Phase I trials, and manufacturing responsibilities shift to GSK. Chugai will receive royalties on future sales and a share of third-party sublicensing income. This follows a previous collaboration agreement from January 2025.
- Chugai signed an exclusive worldwide license with GSK for anti-dengue antibody AID351 on Aug. 17, 2026. * GSK gains rights to develop, manufacture, commercialize AID351 for flavivirus infections, including dengue fever. * Clinical development shifts to GSK, including Phase I trials; manufacturing also moves to GSK. * Chugai to receive royalties on future sales; also eligible for a share of any third-party sublicensing income. * Deal follows a Jan. 30, 2025 collaboration agreement; program originated from work with A*STAR SIgN and National University of Singapore. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chugai Pharmaceutical Co. Ltd. published the original content used to generate this news brief on August 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here